Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
The primary objective of the study is to investigate the influence of multiple doses of BAY1817080 on the pharmacokinetics of rosuvastatin given concomitantly. Secondary objective is to investigate the safety of BAY1817080.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participant is healthy as determined by the investigator
White or Black race
Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m² at screening
Body weight of at least 50 kg at screening
You may not be if
Known or suspected allergy or hypersensitivity to BAY1817080, rosuvastatin or any of their excipients
Asian race
Contraindications to rosuvastatin
Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, within 1 week prior to the first study intervention administration or during the study until follow-up (occasional use of ibuprofen is permissible)
History of or positive COVID-19 test or contact with COVID-19 positive subject in past 4 weeks
Clareo Health | Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
